Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy.
Jii Bum LeeHyung Soon ParkSu Jin ChoiSeong Gu HeoHo Jung AnHye Ryun KimMin Hee HongSun Min LimKyle ChangKatie QuinnJustin OdegaardByoung Yong ShimByoung Chul ChoPublished in: Therapeutic advances in medical oncology (2022)
High pTMB (⩾19 mut/Mb) is significantly associated with CBR in patients with NSCLC treated with anti-PD-1 agents.